All news

Danaher CEO targets 4% to 5% core growth by 2027

Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash

Danaher's new CEO Julie Sawyer Montgomery, speaking at the UBS Global Healthcare Conference, set a 2027 target of 4% to 5% core growth excluding respiratory, with aspirations for high-single-digit growth over the long term. The plan leans on commercial execution, innovation, talent and disciplined capital allocation, focused on AI drug discovery, diagnostics, Cytiva and China.

Read original source

DHR company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.